Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 131, Issue 9, 2005, Pages 581-584

  Michener, Chad M ^a   Peterson, Gertrude ^a   Kulp, Barbara ^a   Webster, Kenneth D ^a   Markman, Maurie ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy; Taxanes; Uterine corpus

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; MEGESTROL ACETATE; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CARCINOMA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HISTOLOGY; HUMAN; HUMAN TISSUE; MEDICAL RECORD; MYALGIA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; TOXICITY; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 27644503514     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-005-0676-x     Document Type: Article

References (20)

1. Ball HG, Blessing JA et al (1996) A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62(2):278-281
2. Barakat RR, Grigsby PW et al (2000) Corpus: epithelial tumors. In: Hoskins WJ Principles and practice of gynecologic oncology. Lippincott Williams and Wilkins, Philadelphia, pp 919-959
3. Barrett RJ, Blessing JA et al (1993) Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 16(6):494-496
4. Blessing JA (1990) Design analysis and interpretation of chemotherapy trials in gynecologic cancer. In: Deppe G Chemotherapy of gynecologic cancer. Alan R. Liss Inc, Scientific and Medical Publications, New York, pp 63-97
5. Burke TW, Munkarah A et al (1993) Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 51(3):397-400
6. Burke TW, Stringer CA et al (1991) Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 40(3):264-267
7. Dimopoulos MA, Papadimitriou CA et al (2000) Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 78(1):52-57
8. du Bois A, Luck HJ et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320-1329
9. Duk JM, Aalders JG et al (1986) CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 155(5):1097-1102
10. Fleming GF, Fowler JM et al (2001) Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol 19(4):1021-1029
11. Hoskins PJ, Swenerton KD et al (2001) Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19(20):4048-4053
12. Le TD, Yamada SD et al (1999) Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with taxol and carboplatin. Gynecol Oncol 73(3):461-463
13. Lincoln S, Blessing JA et al (2003) Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88(3):277-281
14. Markman M, Kennedy A et al (2000) Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78(3Pt1):369-372
15. Neijt JP, du Bois A (1999) Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer. Semin Oncol 26(1Suppl2):78-83
16. Price FV, Edwards RP et al (1997) A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Semin Oncol 24(5Suppl15):S15-78-S15-S82
17. Skarlos DV, Aravantinos G et al (1997) Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Semin Oncol 24(5Suppl15):S15-57-S15- 61
18. Thigpen JT, Blessing JA et al (1994) A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 12(7):1408-1414
19. Vasuratna A, Kudelka AP et al (1998) Prolonged remission of endometrial cancer with paclitaxel and carboplatin. Anticancer Drugs 9(3):283-285
20. Weber B, Mayer F et al (2003) What is the best chemotherapy regimen in recurrent or advanced endometrial carcinoma? Preliminary results. ProcASCO 22:1819